Study ID: C38072/3084

Study Title

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Teva Identifier

C38072/3084

ClinicalTrials.gov Identifier

NCT01508936

Study Status

Completed

Trial Condition(s)

Eosinophilic Asthma

Interventions

Drug: Reslizumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 65 Years

Trial Duration

02/01/2012 - 08/01/2013

Phase

Phase 3

Study Type

Interventional